Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients

Medicus Pharma Ltd.

Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).
Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.
Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Smith

Chief Operating Officer

MDCX · Medicus Pharma Ltd.

Effective: 2025-06-30
Filed: Jun 23, 2025 23:59 UTC

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").

Source: SEC EDGAR

accession 0001062993-25-012044

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.